Lorbrena (lorlatinib) — United Healthcare
large B-Cell lymphoma
Initial criteria
- Diagnosis of anaplastic large cell lymphoma (ALCL) OR large B-Cell lymphoma
- Disease is relapsed or refractory
- Disease is ALK-positive
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Lorbrena therapy
Approval duration
12 months